The L162V polymorphism of the peroxisome proliferator activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 3, 2009, Pages 113-118

  Silbernagel, G ^a   Stefan, N ^a   Hoffmann, M M ^b   Machicao Arano, F ^a   Machann, J ^a   Schick, F ^a   Winkelmann, B R ^c   Boehm, B O ^d   Haring H U ^a   Fritsche, A ^a   Marz W ^e,f  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Cardiology Group Frankfurt Sachsenhausen   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f SYNLAB ACADEMY   (Germany)

Author keywords

Body fat composition; L162V; Obesity; Peroxisome proliferator activated receptor alpha; Single nucleotide polymorphism; Type 2 diabetes

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ARTICLE; BODY FAT; BODY MASS; COHORT ANALYSIS; FEMALE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BODY FAT DISTRIBUTION; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LEUCINE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; RISK FACTORS;

EID: 62749204385     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0028-1082069     Document Type: Article

References (27)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 (Suppl 1): S43-S48
2. Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M, STOP-NIDDM Study Group. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-α gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2007; 56 (4): 1181-1186
3. Bosse Y, Despres JP, Bouchard C, Perusse L, Vohl MC. The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity. Obes Res 2003; 11 (7): 809-816
4. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med 2001; 79: 198-204
5. Faul MM, Grese TA. Selective RXR modulators for the treatment of type II diabetes. Curr Opin Drug Discov Devel 2002; 5 (6): 974-985
6. Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, Hurel SJ, Humphries SE. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005; 54 (2): 582-586
7. Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvänne M. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105 (12): 1440-1445
8. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000; 43 (5): 673-680
9. Gouni-Berthold I, Giannakidou E, Müller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W. Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am Heart J 2004; 147 (6): 1117-1124
10. Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fiévet C, Staels B. Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 2006; 55: 1605-1613
11. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARalpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571-580
12. Love-Gregory LD, Wasson J, Ma J, Jin CH, Glaser B, Suarez BK, Permutt MA. A common polymorphism in the upstream promoter region of the hepatocyte nuclear factor-4 alpha gene on chromosome 20q is associated with type 2 diabetes and appears to contribute to the evidence for linkage in an ashkenazi jewish population. Diabetes 2004; 53 (4): 1134-1140
13. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22 (9): 1462-1470
14. Muller YL, Bogardus C, Pedersen O, Baier L. A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 2003; 52 (3): 895-898
15. Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM. The peroxisome proliferator-activated receptor gamma coactivator-1 alpha gene (PGC-1alpha) is not associated with type 2 diabetes mellitus or body mass index among Hispanic and non Hispanic Whites from Colorado. Exp Clin Endocrinol Diabetes 2007; 115 (4): 268-275
16. Robitaille J, Brouillette C, Houde A, Lemieux S, Pérusse L, Tchernof A, Gaudet D, Vohl MC. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004; 49 (9): 482-489
17. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ. The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000; 10 (4): 321-333
18. Schäfer SA, Müssig K, Stefan N, Häring HU, Fritsche A, Balletshofer BM. Plasma homocysteine concentrations in young individuals at increased risk of type 2 diabetes are associated with subtle differences in glomerular filtration rate but not with insulin resistance. Exp Clin Endocrinol Diabetes 2006; 114 (6): 306-309
19. Shin MJ, Kanaya AM, Krauss RM. Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 2008; 198 (2): 313-319
20. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O, Spieth C, Weigert C, Fritsche A, Stumvoll M, Häring HU. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005; 48 (11): 2282-2291
21. Stefan N, Thamer C, Staiger H, Machicao F, Machann J, Schick F, Venter C, Niess A, Laakso M, Fritsche A, Häring HU. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 2007; 92 (5): 1827-1833
22. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-J ä rvinen H, Haeften T Van, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23 (3): 295-301
23. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22 (5): 805-810
24. Tordjman K, Bernal-Mizrachi C, Zemany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, Semenkovich CF. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 2001; 107 (8): 1025-1034
25. Uthurralt J, Gordish-Dressman H, Bradbury M, Tesi-Rocha C, Devaney J, Harmon B, Reeves EK, Brandoli C, Hansen BC, Seip RL, Thompson PD, Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Gordon PM, Hoffman EP. PPARalpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med Genet 2007; 8: 55
26. Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde G, Cellier C, Faith JM, Després JP, Morgan K, Hudson TJ. Molecular scanning of the human PPARa gene: association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41 (6): 945-952
27. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J, LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health). Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovacular disease. Pharmacogenomics 2001; 2 (1Suppl 1): S1-S73